Day: August 19, 2024

Q2 Digital Colocation Business Revenue increased 77% Y/YQ2 Energy Management Business Revenue increased 70% Y/YCompany Optimized and Reduced Q2 SG&A Expenses by 42% Y/YQ2 2024 Total Revenue Increased 24% Y/Y and Increased 75% YTD (6 months) of 2024 MIDLAND, Pa., Aug. 19, 2024 (GLOBE NEWSWIRE) — Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson”, “the Company”), a publicly traded digital infrastructure provider headquartered in the United States, today announced its unaudited financial and operational results for the second quarter of fiscal year 2024 ended June 30, 2024. Rahul Mewawalla, CEO and President of Mawson, said, “We are pleased to deliver another solid quarter, including growth of our digital colocation business with revenue increasing by 77% this quarter, and growth of our energy management business...

OWINGS MILLS, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) — Universal Security Instruments, Inc. (NYSE Amex: UUU) today announced results for its fiscal quarter ended June 30, 2024. The Company reported sales of $4,598,516 for the quarter ended June 30, 2024, versus $6,698,771 for the comparable period of last year. The Company reported a net loss of $442,206 or $(0.19) per basic and diluted share, compared to net income of $165,130, or $0.07 per basic and diluted share, for the same period last year. Harvey Grossblatt – President and CEO said: “Sales were lower due to supply chain delays in obtaining components for the Company’s security products, and gross margins were reduced in the June quarter by higher ocean freight and component costs.”      UNIVERSAL SECURITY INSTRUMENTS, INC. is a distributor of safety and security devices....

Revenue of $58.7 million for Q2 2024 and $124.7 for 1H 2024 Net loss of $11.6 million for Q2 2024 and $17.9 for 1H 2024 Gross profit (exclusive of depreciation and amortization) of $12.6 million for Q2 2024 and $31.2 for 1H 2024 Media margin of $15.7 million for Q2 2024 and $37.8 million for 1H 2024 Adjusted EBITDA of negative $4.5 million for Q2 2024 and $3.8 million for 1H 2024 Adjusted net loss of $7.3 million for Q2 2024 and $11.5 for 1H 2024 NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported financial results for the second quarter ended June 30, 2024. Don Patrick, Fluent’s Chief Executive Officer, commented, “We continued to drive key strategic initiatives in the second quarter of 2024 to accelerate our strategic pivot as we position...

Record Fourth Quarter Revenue and Earnings Per Share Exceed Guidance BANGKOK, Thailand, Aug. 19, 2024 (GLOBE NEWSWIRE) — Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced its financial results for its fourth quarter and fiscal year ended June 28, 2024. Seamus Grady, Chief Executive Officer of Fabrinet, said, “Our strong fourth quarter results capped a remarkable fiscal year, representing our fourth quarter in a row of record revenue, and record earnings per share, both of which were above our guidance ranges. We remain optimistic about our future, with numerous drivers that position us to extend our track record of success into fiscal year 2025.” Fourth Quarter...

Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes Secured $7.6 Million in Upsized Financing Round Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the second quarter ended June 30, 2024 as well as recent company highlights. “Moving into my...

BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second quarter 2024. Recent Business Highlights Delivered oral presentation on updated data from ongoing Phase 1(b) trial of CUE-101 as a first line (1L) therapy in human papillomavirus positive (HPV+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), with standard of care (SOC) checkpoint inhibitor (CPI) KEYTRUDA® (pembrolizumab) and as a monotherapy in second line and beyond (2L+) HPV+ R/M HNSCC, as well as a poster presentation on CUE-102 in Wilms’ Tumor 1 (WT1) positive cancers at the 2024 American Society of Clinical Oncology...